3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
3
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Carcinoma, Renal Cell
2
Bites and Stings
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Oligoprogressive
1
Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Sorafenib
12
Radiosurgery
5
Gemcitabine
5
Capecitabine
5
Bevacizumab
5
Radiotherapy
4
Fluorouracil
4
Doxorubicin
4
Sunitinib
3
Oxaliplatin
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
seocalcitol
2
regorafenib
2
phosphomannopentaose sulfate
2
atezolizumab
2
Thiotepa
2
Radiofrequency Ablation
2
Melphalan
2
Ifosfamide
2
Granulocyte Colony-Stimulating Factor
2
Fluorodeoxyglucose F18
2
Filgrastim
2
Dexamethasone
2
Cisplatin
2
Chemoembolization, Therapeutic
2
Carboplatin
2
Busulfan
2
Brachytherapy
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Liver Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT05497453
2025-02-03
MYCHELANGELO I
Omega Therapeutics
Phase 1/2
Terminated
24 enrolled